Abstract
Neurodegenerative disorders are devastating human diseases that include Parkinsons, Huntingtons, Alzheimers, amyotrophic lateral sclerosis, and the frontal temporal dementias. Although the clinical manifestations of these disorders have been known for quite some time, our understanding of the molecular underpinnings is only starting to emerge. Protein misfolding and aggregation is a common hallmark among these diseases, and produce a number of cellular and functional alterations. The loss of dopaminergic neurons in the substantia nigra justified the use of dopaminergic therapies in patients. However, these strategies do not appear to confer disease-modifying effects, and do not prevent progression. The idea that neurotrophic factors might promote cell survival is an attractive one. Existing evidence from clinical trials is currently inconclusive, but some patients display clear clinical benefits. Thus, the current challenge is to develop novel strategies that make the use of neurotrophic factors more consistent.
Keywords: Parkinson's disease, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, glial cell line derived neurotrophic factor, se, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, frontal temporal dementias, parkinsonism, BDNF, GDNF, NGF, (MAPK) pathway, neurturin, neublastin, enovin, persephin, (PSPN), TrK-mediated neurotrophin signaling, hyponatremia, Unified Parkinson's Disease Rating Scale, UPDRS, dyskinesias, L-Dopa-induced dyskinesias
CNS & Neurological Disorders - Drug Targets
Title: Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
Volume: 9 Issue: 6
Author(s): Maria Jose Diogenes and Tiago Fleming Outeiro
Affiliation:
Keywords: Parkinson's disease, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, glial cell line derived neurotrophic factor, se, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, frontal temporal dementias, parkinsonism, BDNF, GDNF, NGF, (MAPK) pathway, neurturin, neublastin, enovin, persephin, (PSPN), TrK-mediated neurotrophin signaling, hyponatremia, Unified Parkinson's Disease Rating Scale, UPDRS, dyskinesias, L-Dopa-induced dyskinesias
Abstract: Neurodegenerative disorders are devastating human diseases that include Parkinsons, Huntingtons, Alzheimers, amyotrophic lateral sclerosis, and the frontal temporal dementias. Although the clinical manifestations of these disorders have been known for quite some time, our understanding of the molecular underpinnings is only starting to emerge. Protein misfolding and aggregation is a common hallmark among these diseases, and produce a number of cellular and functional alterations. The loss of dopaminergic neurons in the substantia nigra justified the use of dopaminergic therapies in patients. However, these strategies do not appear to confer disease-modifying effects, and do not prevent progression. The idea that neurotrophic factors might promote cell survival is an attractive one. Existing evidence from clinical trials is currently inconclusive, but some patients display clear clinical benefits. Thus, the current challenge is to develop novel strategies that make the use of neurotrophic factors more consistent.
Export Options
About this article
Cite this article as:
Jose Diogenes Maria and Fleming Outeiro Tiago, Neurotrophic Factors as a Protective Strategy in Parkinsons Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237449
DOI https://dx.doi.org/10.2174/187152710793237449 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Editorial: Structural Aspects of Protein Aggregation
Protein & Peptide Letters Are Catechins, Polyphenols in Tea, Good for Your Health?
Current Nutrition & Food Science Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Current Medicinal Chemistry Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry Glutamate Binding-Site Ligands of NMDA Receptors
Current Medicinal Chemistry Functional Genomics of Brain Aging and Alzheimers Disease: Focus on Selective Neuronal Vulnerability
Current Genomics The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Neuroprotective Role of Natural Polyphenols
Current Topics in Medicinal Chemistry New Horizons in the Treatment of Neurological Disorders with Tailorable Gold Nanoparticles
Current Drug Metabolism Trifluoroethanol-induced Activity and Structural Changes in Bos taurus Copper- and Zinc-containing Superoxide Dismutase
Protein & Peptide Letters Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) Stem Cells: An Overview of the Current Status of Therapies for Central and Peripheral Nervous System Diseases
Current Medicinal Chemistry Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research Neurodegenerative Disorders Treatment: The MicroRNA Role
Current Gene Therapy Drug Screening for Huntingtons Disease and other Neurodegenerative Disorders
Current Molecular Pharmacology Molecular Structure of Ionotropic Glutamate Receptors
Current Medicinal Chemistry Potential Gene Therapy Towards Treating Neurodegenerative Disea ses Employing Polymeric Nanosystems
Current Gene Therapy Advanced Techniques for Imaging the Human Spinal Cord: Review of Literature
Current Medical Imaging Kainic Acid-Induced Neurotoxicity: Targeting Glial Responses and Glia-Derived Cytokines
Current Neuropharmacology